BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Corno C, Gatti L, Arrighetti N, Carenini N, Zaffaroni N, Lanzi C, Perego P. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells. Biochem Pharmacol 2017;136:40-50. [PMID: 28404378 DOI: 10.1016/j.bcp.2017.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Vergani E, Beretta GL, Aloisi M, Costantino M, Corno C, Frigerio S, Tinelli S, Dugo M, Accattatis FM, Granata A, Arnaboldi L, Rodolfo M, Perego P, Gatti L. Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma. Front Cell Dev Biol 2022;10:927118. [DOI: 10.3389/fcell.2022.927118] [Reference Citation Analysis]
2 Cimini S, Giaccone G, Tagliavini F, Costantino M, Perego P, Rossi G. P301L tau mutation leads to alterations of cell cycle, DNA damage response and apoptosis: evidence for a role of tau in cancer. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.115043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Salmaggi A, Corno C, Maschio M, Donzelli S, D'Urso A, Perego P, Ciusani E. Synergistic Effect of Perampanel and Temozolomide in Human Glioma Cell Lines. J Pers Med 2021;11:390. [PMID: 34068749 DOI: 10.3390/jpm11050390] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
4 Stamatakos S, Beretta GL, Vergani E, Dugo M, Corno C, Corna E, Tinelli S, Frigerio S, Ciusani E, Rodolfo M, Perego P, Gatti L. Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations. Cancers (Basel) 2021;13:2284. [PMID: 34068792 DOI: 10.3390/cancers13092284] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
5 Corno C, Arrighetti N, Ciusani E, Corna E, Carenini N, Zaffaroni N, Gatti L, Perego P. Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells. Front Cell Dev Biol 2020;8:610. [PMID: 32754596 DOI: 10.3389/fcell.2020.00610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
6 Sartori A, Corno C, De Cesare M, Scanziani E, Minoli L, Battistini L, Zanardi F, Perego P. Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models. Cancers (Basel) 2019;11:E531. [PMID: 31013908 DOI: 10.3390/cancers11040531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
7 Corno C, Perego P. KiSS1 in regulation of metastasis and response to antitumor drugs. Drug Resistance Updates 2019;42:12-21. [DOI: 10.1016/j.drup.2019.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
8 Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck-Noia H, Hagemann IS, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. Mol Cancer Ther 2019;18:389-98. [PMID: 30478151 DOI: 10.1158/1535-7163.MCT-18-0537] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
9 Flem Karlsen K, McFadden E, Flørenes VA, Davidson B. Soluble AXL is ubiquitously present in malignant serous effusions. Gynecol Oncol 2019;152:408-15. [PMID: 30448261 DOI: 10.1016/j.ygyno.2018.11.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, Minoli L, Scanziani E, Argueta C, Landesman Y, Zaffaroni N, Gatti L, Perego P. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. Biochem Pharmacol 2018;147:93-103. [PMID: 29155058 DOI: 10.1016/j.bcp.2017.11.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]